NeuroSigma’s lead product, The Monarch eTNS System, is the first FDA-approved medical device for treating pediatric ADHD. This wearable neurostimulation device, used at home, delivers the benefits of ADHD medications without the associated side effects. NeuroSigma plans to launch the next generation of the Monarch device in the United States in 2025, furthering its mission to improve ADHD treatment.